Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses
and limited treatment interventions. Recently, comprehensive molecular profiles of lung …

Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …

ROS1 is a validated therapeutic target in NSCLC. In a phase I study, the multitargeted MET
proto-oncogene, receptor tyrosine kinase/anaplastic lymphoma kinase/ROS1 inhibitor …

Genetic alterations that lead to constitutive activation of kinases are frequently observed in
cancer. In many cases, the growth and survival of tumor cells rely upon an activated kinase …

The discovery of chromosomal rearrangements involving the anaplastic lymphoma kinase
(ALK) gene in non‐small cell lung cancer (NSCLC) has stimulated renewed interest in …

Rearrangements of the ROS1 gene occur in 1–2% of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes
were recently identified as new targetable genetic aberrations in cases of non-small cell …

Chromosomal rearrangements that lead to oncogenic kinase activation are observed in
many epithelial cancers. These cancers express activated fusion kinases that drive the …